Logo
Paradigm Biopharmaceuticals

Lysosomal Storage Diseases

Bone and joint manifestations, chronic pain and physical disability persist for many people living with a mucopolysaccharidosis, despite haematopoietic stem cell transplantation and enzyme replacement therapy. Paradigm has run two clinical studies of injectable pentosan polysulfate sodium in this setting — in MPS VI and in MPS I. Neither is recruiting.

Participants, MPS VI 12 All receiving enzyme replacement therapy. Two sites in Brazil.
Participants, MPS I 4 Open-label, one centre, over 48 weeks.
Orphan designation status granted 4 Granted by the US FDA and European Commission (EMA) for both indications.

MPS VI · Maroteaux-Lamy syndrome

Status
Complete. Completion declared at Paradigm’s AGM, November 2024
Study code
PARA_MPSVI_001
Design
24-week randomised, double-blind, placebo-controlled; 12 participants; two sites in Brazil
Primary objective
Safety and tolerability of subcutaneous PPS
Orphan designation status granted
US FDA (Jan 2015) and EMA (Aug 2020)

MPS I · Hurler, Hurler-Scheie and Scheie

Status
Complete. Paradigm is seeking a partner to progress the programme
Study code
PARA_MPSI_001
Design
Open-label Phase 2, single centre, 48 weeks; four participants
Primary objective
Safety and tolerability of PPS over 48 weeks
Orphan designation status granted
US FDA (Apr 2020) and EMA (Nov 2014)

Milestones

Significant development milestones for the MPS type I and VI programs

  1. Nov 2014 EMA orphan designation for MPS I, EU/3/14/1359 Complete
  2. 2018 Exclusive licence to develop PPS in lysosomal storage diseases Complete
  3. Aug 2020 EMA orphan designation for MPS VI, EU/3/20/2315 Complete
  4. Aug 2021 Enrolment began in PARA_MPSVI_001 Complete
  5. Feb 2022 PARA_MPSVI_001 study design and progress presented at WORLDSymposium Complete
  6. 2024 PARA_MPSI_001 published in the Journal of Inherited Metabolic Disease Complete
  7. Nov 2024 PARA_MPSVI_001 completion declared at the Annual General Meeting Complete

Potential

There is an unmet need to help manage bone and joint manifestations, chronic pain, and physical disability, key clinical manifestations of MPS I which remain despite treatment with HSCT and ERT. 3 PPS has been shown to reduce GAG levels, inflammatory biomarkers, joint stiffness, and pain in preclinical MPS models and in clinical trials in MPS patients. 6-10

The mechanisms of action of PPS that are relevant to the treatment of MPS include:

  • Reduction in systemic and accumulated GAGs in multiple tissues 11
  • Anti-inflammatory effects via the inhibition of NF-kB resulting in the reduction in pro-inflammatory mediators 12
  • Reduction of the expression of the pain mediator, nerve growth factor (NGF) in osteocytes from degenerating joints 13
  • An ability to inhibit the cartilage degrading enzymes that are related to joint dysfunction observed in MPS 14
Key MPS I Figures

Incidence of live births 4

1/100K

Expected lifespan with severe form, untreated 1

10YRS

Expected lifespan with attenuated form 1

50YRS

Market size (USD/pa) by 2027 5

$828M+

Potential

There is an unmet need to help manage bone and joint manifestations, chronic pain, and physical disability, key clinical manifestations of MPS VI which remain despite treatment with ERT. 4 PPS has been shown to reduce GAG levels, inflammatory biomarkers, joint stiffness, and pain in preclinical MPS models and in clinical trials in MPS patients. 8-11 The mechanisms of action of PPS that are relevant to the treatment of MPS include:

  • Reduction in systemic and accumulated GAGs in multiple tissues 12
  • Anti-inflammatory effects via the inhibition of NF-kB resulting in the reduction in pro-inflammatory mediators 13
  • Reduction in the expression of the pain mediator, nerve growth factor (NGF) in osteocytes from degenerating joints 14
  • An ability to inhibit the cartilage degrading enzymes that are related to joint dysfunction observed in MPS 15
Key MPS VI Figures

Incidence of live births 6

≤1/240K

Expected lifespan with severe form 1

≤20YRS

Expected lifespan with less severe form 1

≤50YRS

Estimated global market size (USD) by 2027 7

$706M+

Where to go from here

If you or someone you care for is living with a mucopolysaccharidosis, neither of Paradigm’s MPS studies is open. The MPS VI study is complete, and the MPS I study is complete and awaiting a partner to progress it. Paradigm is not able to discuss an individual’s eligibility for a clinical trial, or any matter relating to your condition. Your own doctor or metabolic specialist is the right person to talk to about your care.

For investors and potential partners: Paradigm is seeking a partner to progress the MPS I programme. Announcements and disclosures are published in full on this hub.

Important information

Injectable pentosan polysulfate sodium is an investigational medicine in mucopolysaccharidoses. It is not approved for the treatment of any mucopolysaccharidosis in any jurisdiction, and it is not available outside a clinical trial. Nothing on this page is medical advice or an offer of treatment.